Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

Sponsor
AstraZeneca
Study ID
NCT05374603
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, interventional, multiple-center, exploratory Phase II study sponsored by AstraZeneca Investment(China)Co., LTD. to evaluate the efficacy and safety of Savolitinib combine with Durvalumab in Chinese EGFR wild-type locally advanced or metastatic NSCLC patients with MET alteration.

Key Dates

Start date
Nov 15, 2022
Status verified
May 2026
Primary completion
Jan 18, 2027
Completion
Jan 18, 2027

Study Design

Enrollment
47 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Savolitinib combine with Durvalumab
    single-arm

Primary Outcome Measure

PFS [ Time Frame: The analysis will occur when 60 percent PFS event is observed in each cohort, at approximately 10 months after last patient in. ]

Related Studies